Michael Jäger Selected Research

catumaxomab

6/2012	First patient treated with a re-challenge of catumaxomab in recurrent malignant ascites: a case report.
1/2012	Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).
1/2011	Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial.
6/2010	Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.
2/2009	Treatment of malignant pleural effusion with the trifunctional antibody catumaxomab (Removab) (anti-EpCAM x Anti-CD3): results of a phase 1/2 study.
10/2007	Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
7/2007	Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Jäger Research Topics

Disease

11	Neoplasms (Cancer) 01/2012 - 02/2004
7	Ascites 06/2012 - 11/2005
3	Fever (Fevers) 01/2011 - 05/2006
3	Peritoneal Neoplasms 01/2011 - 11/2005
3	Ovarian Neoplasms (Ovarian Cancer) 02/2009 - 07/2007
2	Vomiting 01/2011 - 05/2006
2	Bites and Stings (Sting) 01/2010 - 11/2008
2	Breast Neoplasms (Breast Cancer) 05/2009 - 05/2006
2	Nausea 02/2009 - 05/2006
1	COVID-19 01/2022
1	Atopic Dermatitis (Atopic Eczema) 03/2021
1	Pruritus (Itching) 03/2021
1	Carcinoma (Carcinomatosis) 01/2012
1	Abdominal Pain (Pain, Abdominal) 01/2011
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2011
1	Malignant Pleural Effusion 02/2009
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2007
1	Headache (Headaches) 05/2006
1	Lymphopenia (Lymphocytopenia) 05/2006
1	Melanoma (Melanoma, Malignant) 02/2004

Drug/Important Bio-Agent (IBA)

7	catumaxomabIBA 06/2012 - 07/2007
7	Epithelial Cell Adhesion MoleculeIBA 06/2012 - 11/2005
5	AntibodiesIBA 01/2022 - 02/2004
4	AntigensIBA 05/2009 - 02/2004
2	CytokinesIBA 01/2012 - 02/2004
2	LigandsIBA 01/2010 - 11/2008
2	ertumaxomabIBA 05/2009 - 05/2006
2	EnzymesIBA 02/2009 - 05/2006
2	Monoclonal AntibodiesIBA 02/2009 - 10/2007
1	BNT162 VaccineIBA 01/2022
1	2019-nCoV Vaccine mRNA-1273IBA 01/2022
1	SARS-CoV-2 spike proteinIBA 01/2022
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2012
1	MetalsIBA 01/2010
1	Trastuzumab (Herceptin)FDA Link 05/2009
1	human ERBB2 proteinIBA 05/2009
1	Immunoglobulins (Immunoglobulin)IBA 02/2009
1	Pharmaceutical PreparationsIBA 05/2006
1	PerforinIBA 02/2004
1	Proteoglycans (Proteoglycan)IBA 02/2004
1	GangliosidesIBA 02/2004

Therapy/Procedure

4	Therapeutics 01/2012 - 02/2004
3	Immunotherapy 01/2011 - 11/2005
2	Aftercare (After-Treatment) 01/2012 - 02/2009
1	Baths 03/2021
1	Drug Therapy (Chemotherapy) 02/2009